Archive — US — techcrunch
OpenAI and the FDA are reportedly discussing AI for drug evaluations
OpenAI has engaged with the FDA to discuss the implementation of AI, specifically a project called cderGPT, to enhance the drug evaluation process, which traditionally takes over a decade, by making it more efficient, though reliability concerns persist.
Key points
- OpenAI met with FDA officials to discuss AI applications in drug evaluations.
- The focus is on a project named cderGPT for the Center for Drug Evaluation.
- Current drug development processes often take over a decade to complete.
- The goal is to shorten that timeline with AI's assistance.
- Concerns exist about the reliability of AI models in drug evaluations.
Why it matters
- AI in healthcare has gained momentum, with numerous tech companies exploring applications in drug discovery and patient care.
- Historically, drug evaluation processes have criticized for their long timelines; AI could address this issue.
- As of 2025, trends indicate a rise in hybrid models incorporating AI for more efficient healthcare solutions.
The collaboration between OpenAI and the FDA represents a significant step towards modernizing drug evaluations, which could reshape the pharmaceutical landscape, provided the reliability of AI is adequately addressed.